Literature DB >> 23220743

Selective effects of a morphine conjugate vaccine on heroin and metabolite distribution and heroin-induced behaviors in rats.

M D Raleigh1, M Pravetoni, A C Harris, A K Birnbaum, P R Pentel.   

Abstract

Morphine conjugate vaccines have effectively reduced behavioral effects of heroin in rodents and primates. To better understand how these effects are mediated, heroin and metabolite distribution studies were performed in rats in the presence and absence of vaccination. In non-vaccinated rats 6-monoacetylmorphine (6-MAM) was the predominant opioid in plasma and brain as early as 1 minute after i.v. administration of heroin and for up to 14 minutes. Vaccination with morphine conjugated to keyhole limpet hemocyanin (M-KLH) elicited high titers and concentrations of antibodies with high affinity for heroin, 6-MAM, and morphine. Four minutes after heroin administration vaccinated rats showed substantial retention of all three opioids in plasma compared to controls and reduced 6-MAM and morphine, but not heroin, distribution to brain. Administration of 6-MAM rather than heroin in M-KLH vaccinated rats showed a similar drug distribution pattern. Vaccination reduced heroin-induced analgesia and blocked heroin-induced locomotor activity throughout 2 weeks of repeated testing. Higher serum opioid-specific antibody concentrations were associated with higher plasma opioid concentrations, lower brain 6-MAM and morphine concentrations, and lower heroin-induced locomotor activity. Serum antibody concentrations over 0.2 mg/ml were associated with substantial effects on these measures. These data support a critical role for 6-MAM in mediating the early effects of i.v. heroin and suggest that reducing 6-MAM concentration in brain is essential to the efficacy of morphine conjugate vaccines.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23220743      PMCID: PMC3558830          DOI: 10.1124/jpet.112.201194

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  41 in total

1.  The pharmacologic effects of heroin in relationship to its rate of biotransformation.

Authors:  E L WAY; J W KEMP; J M YOUNG; D R GRASSETTI
Journal:  J Pharmacol Exp Ther       Date:  1960-06       Impact factor: 4.030

2.  Pharmacokinetics of heterologous and homologous immunoglobulin G, F(ab')2 and Fab after intravenous administration in the rat.

Authors:  M I Bazin-Redureau; C B Renard; J M Scherrmann
Journal:  J Pharm Pharmacol       Date:  1997-03       Impact factor: 3.765

3.  Species differences in hydrolysis of isocarbacyclin methyl ester (TEI-9090) by blood esterases.

Authors:  T Minagawa; Y Kohno; T Suwa; A Tsuji
Journal:  Biochem Pharmacol       Date:  1995-05-17       Impact factor: 5.858

4.  Comparison of intravenous and intranasal heroin self-administration by morphine-maintained humans.

Authors:  S D Comer; E D Collins; R B MacArthur; M W Fischman
Journal:  Psychopharmacology (Berl)       Date:  1999-04       Impact factor: 4.530

5.  Human erythrocyte but not brain acetylcholinesterase hydrolyses heroin to morphine.

Authors:  A Y Salmon; Z Goren; Y Avissar; H Soreq
Journal:  Clin Exp Pharmacol Physiol       Date:  1999-08       Impact factor: 2.557

6.  Mecamylamine blocks the development of tolerance to nicotine in rats: implications for the mechanisms of tolerance.

Authors:  S E McCallum; A R Caggiula; L H Epstein; S Saylor; T Ploskina; A F Sved
Journal:  Psychopharmacology (Berl)       Date:  1999-01       Impact factor: 4.530

7.  Vaccine pharmacotherapy for the treatment of cocaine dependence.

Authors:  Bridget A Martell; Ellen Mitchell; James Poling; Kishor Gonsai; Thomas R Kosten
Journal:  Biol Psychiatry       Date:  2005-07-15       Impact factor: 13.382

8.  Effects of naloxone on heroin-, amphetamine- and caffeine-stimulated locomotor activity in the rat.

Authors:  N R Swerdlow; F J Vaccarino; G F Koob
Journal:  Pharmacol Biochem Behav       Date:  1985-09       Impact factor: 3.533

9.  Stability of heroin, 6-monoacetylmorphine, and morphine in biological samples and validation of an LC-MS assay for delayed analyses of pharmacokinetic samples in rats.

Authors:  Jessica M Jones; Michael D Raleigh; Paul R Pentel; Theresa M Harmon; Daniel E Keyler; Rory P Remmel; Angela K Birnbaum
Journal:  J Pharm Biomed Anal       Date:  2012-11-15       Impact factor: 3.935

10.  Heroin: analgesia, toxicity and disposition in the mouse.

Authors:  J G Umans; C E Inturrisi
Journal:  Eur J Pharmacol       Date:  1982-12-03       Impact factor: 4.432

View more
  30 in total

1.  A Fentanyl Vaccine Alters Fentanyl Distribution and Protects against Fentanyl-Induced Effects in Mice and Rats.

Authors:  Michael D Raleigh; Federico Baruffaldi; Samantha J Peterson; Morgan Le Naour; Theresa M Harmon; Jennifer R Vigliaturo; Paul R Pentel; Marco Pravetoni
Journal:  J Pharmacol Exp Ther       Date:  2018-11-08       Impact factor: 4.030

2.  Dynamic vaccine blocks relapse to compulsive intake of heroin.

Authors:  Joel E Schlosburg; Leandro F Vendruscolo; Paul T Bremer; Jonathan W Lockner; Carrie L Wade; Ashlee A K Nunes; G Neil Stowe; Scott Edwards; Kim D Janda; George F Koob
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-06       Impact factor: 11.205

3.  Comparison of (+)- and (-)-Naloxone on the Acute Psychomotor-Stimulating Effects of Heroin, 6-Acetylmorphine, and Morphine in Mice.

Authors:  Guro Søe Eriksen; Jannike Mørch Andersen; Fernando Boix; Marianne Skov-Skov Bergh; Vigdis Vindenes; Kenner C Rice; Marilyn A Huestis; Jørg Mørland
Journal:  J Pharmacol Exp Ther       Date:  2016-06-08       Impact factor: 4.030

Review 4.  Development of vaccines to treat opioid use disorders and reduce incidence of overdose.

Authors:  Marco Pravetoni; Sandra D Comer
Journal:  Neuropharmacology       Date:  2019-06-04       Impact factor: 5.250

Review 5.  Conjugate Vaccine Immunotherapy for Substance Use Disorder.

Authors:  Paul T Bremer; Kim D Janda
Journal:  Pharmacol Rev       Date:  2017-07       Impact factor: 25.468

6.  Efficacy, but not antibody titer or affinity, of a heroin hapten conjugate vaccine correlates with increasing hapten densities on tetanus toxoid, but not on CRM197 carriers.

Authors:  Rashmi Jalah; Oscar B Torres; Alexander V Mayorov; Fuying Li; Joshua F G Antoline; Arthur E Jacobson; Kenner C Rice; Jeffrey R Deschamps; Zoltan Beck; Carl R Alving; Gary R Matyas
Journal:  Bioconjug Chem       Date:  2015-06-05       Impact factor: 4.774

Review 7.  Biologics to treat substance use disorders: Current status and new directions.

Authors:  Marco Pravetoni
Journal:  Hum Vaccin Immunother       Date:  2016-07-21       Impact factor: 3.452

8.  Effectiveness and selectivity of a heroin conjugate vaccine to attenuate heroin, 6-acetylmorphine, and morphine antinociception in rats: Comparison with naltrexone.

Authors:  Kathryn L Schwienteck; Steven Blake; Paul T Bremer; Justin L Poklis; E Andrew Townsend; S Stevens Negus; Matthew L Banks
Journal:  Drug Alcohol Depend       Date:  2019-08-24       Impact factor: 4.492

9.  Reduced antinociception of opioids in rats and mice by vaccination with immunogens containing oxycodone and hydrocodone haptens.

Authors:  Marco Pravetoni; Morgan Le Naour; Ashli M Tucker; Theresa M Harmon; Tara M Hawley; Philip S Portoghese; Paul R Pentel
Journal:  J Med Chem       Date:  2013-01-15       Impact factor: 7.446

10.  Synthesis and immunological effects of heroin vaccines.

Authors:  Fuying Li; Kejun Cheng; Joshua F G Antoline; Malliga R Iyer; Gary R Matyas; Oscar B Torres; Rashmi Jalah; Zoltan Beck; Carl R Alving; Damon A Parrish; Jeffrey R Deschamps; Arthur E Jacobson; Kenner C Rice
Journal:  Org Biomol Chem       Date:  2014-10-07       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.